An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004

Trial Profile

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms Accordance-OLE
  • Sponsors Intec Pharma
  • Most Recent Events

    • 03 Dec 2017 Planned End Date changed from 1 Sep 2018 to 1 Dec 2019.
    • 03 Dec 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2019.
    • 29 Mar 2017 According to an Intec Pharma media release, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top